Long-term Study of ADVM-022 in Neovascular (Wet) AMD [OPTIC-EXT]
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT04645212 |
Recruitment Status :
Active, not recruiting
First Posted : November 27, 2020
Last Update Posted : February 14, 2023
|
Tracking Information | |||||
---|---|---|---|---|---|
First Submitted Date | November 20, 2020 | ||||
First Posted Date | November 27, 2020 | ||||
Last Update Posted Date | February 14, 2023 | ||||
Actual Study Start Date | December 14, 2020 | ||||
Estimated Primary Completion Date | June 2025 (Final data collection date for primary outcome measure) | ||||
Current Primary Outcome Measures |
Type, severity and incidence of ocular and systemic adverse events (AEs). [ Time Frame: 156 weeks ] Type, severity and incidence of ocular and systemic adverse events
|
||||
Original Primary Outcome Measures | Same as current | ||||
Change History | |||||
Current Secondary Outcome Measures |
|
||||
Original Secondary Outcome Measures | Same as current | ||||
Current Other Pre-specified Outcome Measures | Not Provided | ||||
Original Other Pre-specified Outcome Measures | Not Provided | ||||
Descriptive Information | |||||
Brief Title | Long-term Study of ADVM-022 in Neovascular (Wet) AMD [OPTIC-EXT] | ||||
Official Title | A Long-term Study of ADVM-022 in Neovascular (Wet) AMD - OPTIC Extension | ||||
Brief Summary | ADVM-022-07 is an observational long-term extension (OPTIC-EXT) study assessing safety and efficacy of ADVM-022 gene therapy product, in subjects with neovascular, or exudative (wet), age-related macular degeneration (nAMD). | ||||
Detailed Description | ADVM-022 (AAV.7m8-aflibercept) is a gene therapy product developed for the treatment of neovascular (wet) age-related macular degeneration (wet AMD). Wet AMD is a serious condition and the leading cause of blindness in the elderly. The available therapies for treating wet AMD require life-long intravitreal (IVT) injections every 4-12 weeks to maintain efficacy. A one-time IVT administration of ADVM-022 has the potential to treat wet AMD by providing durable expression of therapeutic levels of intraocular anti-VEGF protein (aflibercept) and maintaining the vision of patients. ADVM-022 is designed to reduce the current treatment burden which often results in undertreatment and vision loss in patients with wet AMD receiving anti-VEGF therapy in clinical practice. ADVM-022-07 is an observational long-term extension (OPTIC-EXT) study assessing safety and efficacy of ADVM-022 gene therapy product, in subjects with neovascular, or exudative (wet), age-related macular degeneration (nAMD). To evaluate potential long-term outcomes of ADVM-022, the OPTIC-EXT will follow subjects previously treated in the OPTIC parent study (Clinical Protocol No. ADVM-022-01 [OPTIC] (NCT03748784)). Subjects will roll over from the OPTIC parent study and will be followed for 3 additional years, following completion of the preceding 2-year assessment period in the OPTIC parent study. There is no investigational treatment administered in this study. |
||||
Study Type | Observational | ||||
Study Design | Observational Model: Cohort Time Perspective: Prospective |
||||
Target Follow-Up Duration | Not Provided | ||||
Biospecimen | Not Provided | ||||
Sampling Method | Non-Probability Sample | ||||
Study Population |
|
||||
Condition |
|
||||
Intervention | Biological: ADVM-022
Long term follow-up of subjects that received ADVM-022
Other Name: AAV.7m8-aflibercept
|
||||
Study Groups/Cohorts | 1
Subjects with wet AMD who received any dose of ADVM-022 in a prior clinical study.
Intervention: Biological: ADVM-022
|
||||
Publications * | Not Provided | ||||
* Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline. |
|||||
Recruitment Information | |||||
Recruitment Status | Active, not recruiting | ||||
Actual Enrollment |
23 | ||||
Original Estimated Enrollment |
30 | ||||
Estimated Study Completion Date | June 2025 | ||||
Estimated Primary Completion Date | June 2025 (Final data collection date for primary outcome measure) | ||||
Eligibility Criteria | Inclusion Criteria:
Exclusion Criteria:
|
||||
Sex/Gender |
|
||||
Ages | 50 Years and older (Adult, Older Adult) | ||||
Accepts Healthy Volunteers | No | ||||
Contacts | Contact information is only displayed when the study is recruiting subjects | ||||
Listed Location Countries | United States | ||||
Removed Location Countries | |||||
Administrative Information | |||||
NCT Number | NCT04645212 | ||||
Other Study ID Numbers | ADVM-022-07 | ||||
Has Data Monitoring Committee | No | ||||
U.S. FDA-regulated Product |
|
||||
IPD Sharing Statement |
|
||||
Current Responsible Party | Adverum Biotechnologies, Inc. | ||||
Original Responsible Party | Same as current | ||||
Current Study Sponsor | Adverum Biotechnologies, Inc. | ||||
Original Study Sponsor | Same as current | ||||
Collaborators | Not Provided | ||||
Investigators |
|
||||
PRS Account | Adverum Biotechnologies, Inc. | ||||
Verification Date | February 2023 |